Glow Lifetech Corp. Completes Share Payment to Swiss PharmaCan AG
December 20, 2024
Toronto, Ontario–(Newsfile Corp. – December 20, 2024) – Glow Lifetech Corp. (CSE: GLOW) (OTC Pink: GLWLF) (FSE: 9DO) (“Glow” or the “Company”) announces that, further to its news release dated December 12, 2024, it has issued 10,000,000 common shares (the “Shares”) at a deemed price of $0.20 per Share to Swiss PharmaCan AG (the “Seller”) as the final payment (the “Share Payment”) under the Share Exchange Agreement dated June 18, 2020, and amended as of December 12, 2024 (the “Amendment”), among the Seller, Swiss Pharma Corp. (“Swiss Pharma”), and the Company (the “Share Exchange Agreement”) in connection with the Company’s acquisition of all outstanding shares of Swiss Pharma. The Amendment reduced the total number of Shares issuable to the Seller under the Share Exchange Agreement from 30,000,000 to 15,000,000.
Glow Lifetech Corp. has successfully completed the Share Payment to Swiss PharmaCan AG, marking a significant milestone in the Company’s acquisition of Swiss Pharma. The issuance of 10,000,000 common shares at a price of $0.20 per share signifies the final step in fulfilling the Share Exchange Agreement between the parties.
The Amendment to the Share Exchange Agreement, which reduced the total number of shares issuable to the Seller from 30,000,000 to 15,000,000, reflects the ongoing collaboration and strategic partnership between Glow Lifetech Corp. and Swiss PharmaCan AG. This transaction not only strengthens Glow’s position in the market but also paves the way for future growth and expansion opportunities.
With this latest development, Glow Lifetech Corp. is poised to enhance its product offerings, increase market share, and drive innovation in the healthcare industry. The completion of the Share Payment underscores the Company’s commitment to delivering value to its shareholders and stakeholders while solidifying its position as a key player in the global market.
How This Will Affect Me
As an individual investor, the completion of the Share Payment by Glow Lifetech Corp. to Swiss PharmaCan AG may have a positive impact on your investment in the Company. The issuance of common shares at a deemed price of $0.20 per share signifies a significant milestone in Glow’s acquisition of Swiss Pharma, which could potentially lead to increased shareholder value and growth opportunities in the future.
How This Will Affect the World
The completion of the Share Payment by Glow Lifetech Corp. to Swiss PharmaCan AG highlights the continued growth and collaboration within the healthcare industry. This transaction signals a strategic partnership between the two companies, which could result in the development of innovative healthcare solutions and advancements that benefit society as a whole. The enhanced product offerings and market presence of Glow Lifetech Corp. have the potential to drive positive changes and impact the global healthcare landscape.
Conclusion
In conclusion, the successful completion of the Share Payment by Glow Lifetech Corp. to Swiss PharmaCan AG marks a significant milestone in the Company’s acquisition of Swiss Pharma. This transaction not only strengthens Glow’s position in the market but also sets the stage for future growth and innovation within the healthcare industry. The collaboration between the two companies has the potential to deliver value to shareholders, drive positive changes in the global healthcare landscape, and pave the way for a brighter and more innovative future.
